

Barrier methods – progesterone releasing IUD (Mirena®)

Fact Sheet Compiled by: **Gidona Goodman**

Last Updated: 2010

Fact Sheet Reviewed by: (1) Hester van Bolhuis (2) Steve Unwin

Commercial Name:	Mirena®
Contraceptive Product:	Levonorgestrel
Product Category:	IUD barrier
Product Availability:	Available through human drug distributors
Restrictions and/or permit required by Importing Country:	Current knowledge: no import licence required EGZAC recommend always checking with your local licensing authority
Mechanism of action:	Prevention of endometrial hyperplasia, thickening of cervical mucus and suppression of ovulation
Product information	Used in female apes
Delivery Route and dose:	Intrauterine. Used in female apes EGZAC recommends always reading the manufacturer's data sheet
Females	
Latency to effectiveness:	Immediate if placed during menses in women
Oestrus cycles during contraceptive treatment:	Data deficient
Managing of initial stimulation phase:	See latency to effectiveness above
Use during pregnancy:	Data deficient – possible need for removal during the first trimester
Use during lactation:	Data deficient – can be used post partum
Use in prepubertals or juveniles:	Data deficient – potential for increased risk of pelvic inflammatory disease
Use in seasonal breeders:	N/A
Duration	Data deficient - potentially 4-5 years
Reversibility	Data deficient – potential latency of up to 4 months

Effects on Behaviour	Data deficient
Effects on sexual physical characteristics	Data deficient
Males	
Latency to effectiveness:	N/A
Use in prepubertals or juveniles:	N/A
Use in seasonal breeders:	N/A
Duration and Reversibility	N/A
Effects on Behaviour	N/A
Effects on sexual physical characteristics	N/A
General:	
Side effects	EGZAC recommends always reading the manufacturer's data sheet
Warnings	Due to size has been used in apes only and has on occasion been removed by the apes themselves
Reporting Requirements: In order to increase our knowledge of the efficacy of contraception methods it is recommended that all individuals on contraception be reported to EGZAC	

References:
1) Hasselschwert, D. L. Fontenot, M. B. A disposable vaginal speculum for the chimpanzee (<i>Pan troglodytes</i>). <i>Contemporary Topics in Laboratory Animal Science</i> . 2005. 44: 3, 50-52.
2) Olivier Bourry, Patricia Peignot, Pierre Rouquet Contraception in the chimpanzee: 12-year experience at the CIRMF Primate Centre, Gabon. <i>Journal of medical primateology</i> . 2004 Volume 34 Issue 1, Pages 25 – 34
3) www.fk.cvz.nl/ Farmacotherapeutisch Kompas Netherlands
4) http://www.patentstorm.us/patents/6119696/description.html
5)
6)
7)
8)

Disclaimer: EGZAC endeavours to provide correct and current information on contraception from various sources. As these are prescription only medicines it is the responsibility of the veterinarian to determine the dosage and best treatment for an individual animal under their care. EGZAC can therefore not be held liable for any injury, damage or contraception failure in an animal